Express News | News On TCR2 Therapeutics Inc. (TCRR) Now Under ADAP
Adaptimmune Completes Merger With Fellow Immunology Company TCR2
Adaptimmune Announces Completion of Strategic Combination With TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
TCR2 Therapeutics Target Price Raised to $2.11 From $1.72 at Mizuho Securities
Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
TCR2 Therapeutics (TCRR) Receives a Hold From Mizuho Securities
Recap: TCR2 Therapeutics Q1 Earnings
TCR2 Therapeutics Q1 EPS $(1.03) Down From $(0.76) YoY
Press Release: TCR(2) Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Express News | TCR2 Therapeutics 1Q Loss/Shr $1.03 >TCRR
Global Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights About 250+ Companies and 300+ Drugs
FUBO, MULN and BAK Are Among Pre-market Gainers
Ribbon Communications And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FOCS, ROCC, TCRR
Fate Therapeutics (NASDAQ:FATE) and TCR2 Therapeutics (NASDAQ:TCRR) Head to Head Comparison
TCR2 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR2 Therapeutics Inc. - TCRR
Head to Head Analysis: Fate Therapeutics (NASDAQ:FATE) & TCR2 Therapeutics (NASDAQ:TCRR)
Adaptimmune, TCR Therapeutics Set May 30 for Shareholder Votes on Deal
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ROCC, KBAL, ADAP, TCRR
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RADI, ADAP, TCRR
No Data
No Data